Immunologie - Neue Ansätze zur Immunmodulation und Immuntherapie

Literatur

• 1 Berger J R, Koralnik I J. Progressive multifocal leukoencephalopathy and natalizumab - unforeseen consequences.  New Engl J Med. 2005;  353 414-416
• 2 Beversdorf N, Hanke T, Kerkau T, Hünig T. CD28 superagonists put a break on autoimmunity by preferentially activating CD4+CD25+ regulatory T cells.  Autoimmun Rev. 2006;  5 40-45
• 3 Bluestone J A, St. Clair E W, Turka L A. CTLA4Ig: bridging the basic immunology with clinical application.  Immunity. 2006;  24 233-238
• 4 Breedveld F C, Weisman M H, Kavanaugh A F. et al . The PREMIER study. A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not previous methotrexate treatment.  Arthritis Rheum. 2006;  54 26-37
• 5 Brook M O, Jones N D, Wood K J. Inhibition of chronic rejection and development of tolerogenic T cells after ICOS-ICOSL and CD40-CD40L co-stimulation blockade.  Transplantation. 2005;  80 253-254
• 6 Clark J, Chiang D, Casale T B. Omalizumab in the treatment of allergic respiratory disease.  J Asthma. 2006;  43 87-93
• 7 Duval L, Schmidt H, Kaltoft K. et al . Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with HLA-A2 restricted MART-1 T-cell receptor: a phase I trial in metastatic melanoma.  Clin Cancer Res. 2006;  12 1229-1236
• 8 Feagan B G, Greenberg G R, Wild G. et al . Treatment of ulcerative colitis with a humanized antibody to the α4b7 integrin.  New Engl J Med. 2005;  352 2499-2507
• 9 Genovese M C, Becker J C, Schiff M. et al . Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition.  N Engl J Med. 2005;  353 1114-1123
• 10 Gille J. Antiangiogenic cancer therapies get their act together: current developments and future prospects of growth factor- and growth factor receptor-targeted approaches.  Exp Dermatol. 2006;  15 175-186
• 11 Hopkin M. News and Views: Can super-antibody drugs be tamed?.  Nature. 2006;  440 855-856
• 12 June C H, Blazar B R. Clinical application of expanded CD4+CD25+ cells.  Semin Immunol. 2006;  18 78-88
• 13 Kabelitz D. Immunologie - Gefahrenmanagement im Körper.  Dtsch Med Wochenschr. 2005;  130 1563-1565
• 14 McClung M R, Lewiecki E M, Cohen S B. et al . Denosumab in postmenopausal women with low bone mineral density.  New Engl J Med. 2006;  354 821-831
• 15 Mease P J. Adalimumab: an anti-TNF agent for the treatment of psoriatic arthritis.  Expert Opin Biol Ther. 2005;  5 1491-1504
• 16 Polman C H, O’Connor P W, Havrdova E. et al . A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.  New Engl J Med. 2006;  354 899-910
• 17 Rudick R A, Stuart W H, Calabresi P A. et al . Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.  New Engl J Med. 2006;  354 911-923
• 18 Vincenti F, Larsen C, Durrbach A. et al . Costimulation blockade with belatacept in renal transplantation.  New Engl J Med. 2005;  353 770-781
• 19 Whyte M P. The long and the short of bone therapy.  New Engl J Med. 2006;  354 860-863